Sylvie Chevillard - Concepedia

Author

Sylvie Chevillard

Commissariat à l'Énergie Atomique et aux Énergies Alternatives ORCID

Also Known As

Chevillard, Sylvie, S Chevillard, S. (e) Chevillard, S. CHEVILLARD, S. Chevillard, Sylvie CHEVILLARD, Sylvie Chevillard, Sylvie Chevillard *

144

Publications

4.6K

Citations

H-Index

103

Concepts

All Affiliations

Commissariat à l'Énergie Atomique et aux Énergies Alternatives CEA Paris-Saclay - Etablissement de Fontenay-aux-roses Institut Curie Centre National de la Recherche Scientifique Institut de Radiobiologie Cellulaire et Moléculaire

About

Sylvie Chevillard is an author at Commissariat à l'Énergie Atomique et aux Énergies Alternatives specializing in medicine, radiation oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	30	42	2.3K
2	Engineering	13	13	1K
3	Natural Sciences	6	6	278
4	Health Sciences	4	4	139
5	Biochemistry	1	1	163

Sylvie Chevillard

Publications

3.9K

Citations

H-Index

Page 1

	Year	Citations
Mutations in OGG1, a gene involved in the repair of oxidative DNA damage, are found in human lung and kidney tumours Sylvie Chevillard, J. Pablo Radicella, Céline Levalois, Oncogene Genome InstabilityDna DamageKidney TumoursOxidative Dna DamageOncogenic Agent	1998	225
Specific Uptake and Genotoxicity Induced by Polystyrene Nanobeads with Distinct Surface Chemistry on Human Lung Epithelial Cells and Macrophages Vincent Paget, Samir Dekali, Thierry Kortulewski, PLoS ONE NanoparticlesNanotherapeuticsEngineeringPolystyrene NanobeadsNanotoxicology	2015	166
Redox Regulation of Human OGG1 Activity in Response to Cellular Oxidative Stress Anne Bravard, Monique Vacher, Barbara Gouget, Molecular and Cellular Biology Human Ogg1 ActivityDna DamageRedox RegulationLipid PeroxidationCell Death	2006	163
Doxorubicin-loaded nanospheres bypass tumor cell multidrug resistance C. Cuvier, L. Roblot-Treupel, J Millot, Biochemical Pharmacology NanomedicineEngineeringNano-drug DeliveryDoxorubicin-loaded NanospheresTumor Targeting	1992	157
In vitro biocompatibility of mesoporous metal (III; Fe, Al, Cr) trimesate MOF nanocarriers Romain Grall, Tania Hidalgo, Jozo Delić, Journal of Materials Chemistry B NanoparticlesNanomedicineChemical EngineeringCancer ResistanceEngineering	2015	146
Transforming growth factor‐β and megakaryocytes in the pathogenesis of idiopathic myelofibrosis M. C. Martyré, N. Romquin, Marie‐Caroline Le Bousse‐Kerdilès, British Journal of Haematology	1994	141
Elevated levels of basic fibroblast growth factor in megakaryocytes and platelets from patients with idiopathic myelofibrosis M. C. Martyré, Marie‐Caroline Le Bousse‐Kerdilès, N. Romquin, British Journal of Haematology	1997	140
Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy Sylvie Chevillard, P Pouillart, Chérif Beldjord, Cancer	1996	134
Differential expression of transforming growth factor-beta, basic fibroblast growth factor, and their receptors in CD34+ hematopoietic progenitor cells from patients with myelofibrosis and myeloid metaplasia Marie‐Caroline Le Bousse‐Kerdilès, Sylvie Chevillard, Agnès Charpentier, Blood	1996	129
Carboxylated nanodiamonds are neither cytotoxic nor genotoxic on liver, kidney, intestine and lung human cell lines Vincent Paget, Jacques‐Aurélien Sergent, Romain Grall, Nanotoxicology NanotherapeuticsEngineeringPolystyrene NanobeadsNanotoxicologyOxidative Stress	2013	127

Page 1